



Maharashtra Medical Goods Procurement Authority

Office- 1st Floor, Aarogya Bhawan, Commissionerate of Health Services, Mumbai, D'Mello Road, St. Georges Hospital Compound, Mumbai 400001

Contact Number-022-22611471, 022-22717500 E-mail - maha.mmgsa2023@gmail.com

MMGPA/QA Cell -15/W.D.No.Quot2/Allop/60/2025

Dated:- 18.11.2025

QUOTATION NOTICE

To,

M/s

Subject : - Request for Quotations from eligible NABL-accredited private laboratories for testing of medicines.

This Request for Quotations is issued for obtaining competitive quotations from qualified and approved laboratories for conducting Quality Testing / NABL Testing of medicines as per required standards. The selected laboratory must comply with all regulatory requirements and provide accurate and timely test reports.

Eligibility Criteria for Laboratories:

Only those laboratories meeting the following criteria may submit quotations:

1. Valid FDA License for testing of drugs/medicines.
2. Valid NABL Accreditation Certificate for relevant chemical & microbiological testing parameters.
3. Valid GLP (Good Laboratory Practices) Certificate.
4. Laboratory must have the appropriate testing facility, qualified staff, and equipment.

(Copies of all the above certificates must be attached with the quotation)

Scope of Work:

- The laboratory shall conduct testing of the following medicine samples as per pharmacopeia standards (IP/BP/USP):
- List of Medicines / Items to be tested: List of items as given in the table below.

| Drug Not Check at Lab_DMER | | | |
|----------------------------|--|--|-------------|
| Sr. No. | Item name | Specification | Unit |
| 1 | Contrast Non Ionic Dimer radiography contrast Iodixinol 320mg/ml 100ml bottle | Non Ionic Dimer radiography contrast Iodixinol 320mg/ml 100ml bottle | per bottle |
| 2 | Ortho Phthaladehyde 0.55 % w/v | Solution containing Ortho- Phthaladehyde 0.55 % w/v Required Compatability report of International Standard Manufacturers for commonly used endoscopes i. e. Karl Storz/ Pentax/Fujinon/ Olympus 5 Lit. Required item wise WHO GMP.5 litre Jar | per can |
| 3 | Fat Emulsion I.V. 20% 250 ml Bot. | Fat Emulsion I.V. 20% w/v I.V. fat emulsion for Parenteral nutrition Soyabean oil – 20 gm USP Egg Phopholipid/Lecithin –1.2gm IP Glycerol unhydrous- 2.25gm IP Water fluid – 9 – 250 ml / OR Equivalent 250 ml Bot. | per bottle |
| 4 | Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Iohexol 50ml vial | Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Iohexol | per vial |
| 5 | Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Iohexol 100ml bottle | Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Iohexol | per bottle |
| 6 | Rabies Vaccines Human (cell Culture) potency of not less than 2.5 Units per vial I.P. For ID Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml vial | Rabies Vaccines Human (cell Culture) potency of not less than 2.5 units per vial I.P. For ID Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml vial | per vial |
| 7 | Rabies Vaccines Human (cell Culture) potency of not less than 2.5 units per vial. I.P. For IM Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml Vial | Rabies Vaccines Human (cell Culture) potency of not less than 2.5 units per vial. I.P. For IM Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml Vial | per vial |
| 8 | Probiotic Capsule | Probiotic Capsules Each capsule contains: Lactobacillus rhamnosus GR-1 Lactobacillus reuteri RC-14 1 Billion | per capsule |
| 9 | Alcohol based surgical hand antiseptic Solution 500 ml bottle with dispenser | Active Ingredient in 100 gm- 2- propanol- 45.0 g , 1 Propanol - 30.0 g Alcohol based surgical hand antiseptic containing macetronium ethyl sulphate 0.2 gm / 100 gm or 0.5 % to 1 % chlorhexidine gluconate with suitable emollient & moisturizer 500 ml Container To be accompanied with following valid test reports: 1) EN 1500 (Hygenic Handrub) 2) EN 12791 (surgical Hand Disinfection) 3) EN 14348 (Mycobactericidal activity) 4) EN 14476 (Virucidal activity) 5) ISO 10993-10 (skin Irritation Test) | per bottle |
| 10 | Tetra Starch I V (130/0.4) 6 % 500 ml Bot. | Tetra Starch (130/0.4) 6 % 500 ml Bot. | per bottle |
| 11 | Surfactant for Intratrecheal instillation (natural bovine lung surfactant) Minimum labelled Shelf Life (In Months 18) 4ml | Surfactant for Intratrecheal instillation 25mg/ml (natural bovine lung surfactant) Minimum labelled Shelf Life (In Months 18) 4ml single dose vial | per vial |

| | | | |
|----|---|---|---------------|
| 12 | Surfactant for Intratrecheal instillation (natural bovine lung surfactant) Minimum labelled Shelf Life (In Months 18) 5ml | Surfactant for Intratrecheal instillation (natural bovine lung surfactant) Minimum labelled Shelf Life (In Months 18) 5ml | per vial |
| 13 | Pottassium Peroxomonosulphate 50% w/w 500 gm bottle | Surface Disinfectant containing Pottassium Peroxomonosulphate 50% w/w EN 14476 Required item wise WHO GMP 500 gm | per bottle |
| 14 | Ferrous Fumarate 200 mg + Cyanocobalamine 15 mcg + Folic Acid 1.5 mg. Sustained release OR EQUIVALENT Cap | Ferrous Fumarate 200 mg + Cyanocobalamine 15 mcg + Folic Acid 1.5 mg. Sustained release OR EQUIVALENT Cap | per tablet |
| 15 | Tamsulosin 0.4 mg Tab | Tamsulosin 0.4 mg Tab | per tablet |
| 16 | Colistomithate 3 MIU Inj | Colistimethate sodium 3 million iu Inj | per vial |
| 17 | Monteleukast 10mg and levocetirizine 5mg Tablet | Monteleukast 10mg and levocetirizine 5mg Tablet | per tablet |
| 18 | Multivitamin Syrup (For Therapeutic use only) 200ml | (For Therapeutic use only) Each 5ml contains Vitamin A Palmitate BP 3000 IU Cholecalciferol BP 400 IU Thaimine Hydrochloride BP 2.5 mg Riboflovine BP 2.5 mg Ascorbic Acid BP 50 mg Nicotinamide BP 25 mg Pyridoxine Hydrochloride BP 1 mg Cyanocobalamin BP 3 mcg D-panthenol BP 5mg Flavoured Syrupy base QS Excipients QS | 200 ml Bottle |
| 19 | Hemodialysis solution B.P. with soda bicarbonate 10 Ltr. Jar | Hemodialysis solution B.P. with soda bicarbonate (to be used with Dialysis Machine) 10 Ltr. Jar | per can |
| 20 | Fluocinolone acetonide 0.1% w/w + Methyl Paraben 0.15% + Propyl Paraben 0.05% Ointment 30gm Tube | Fluocinolone acetonide 0.1% w/w + Methyl Paraben 0.15% + Propyl Paraben 0.05% Ointment 30gm Tube | per tube |
| 21 | Black coal tar Disinfectant Fluid R.W.C. not less than 10 Gr -II A I.S.I. mark Latest 5 Litre can | Black coal tar Disinfectant Fluid R.W.C. not less than 10 Gr -II A I.S.I. mark Latest 5 Litre can | per can |
| 22 | Black coal tar Disinfectant Fluid R.W.C. not less than 5 Gr. III I.S.I mark Latest 5 Litre can | Black coal tar Disinfectant Fluid R.W.C. not less than 5 Gr. III I.S.I mark Latest 5 Litre can | per can |
| 23 | Sodium Chloride 0.9% w/v with Potassium chloride 0.30% (20 mcg) I V 500 ml Bottle | Sodium Chloride 0.9% w/v with Potassium chloride 0.30% (20 mcg) 500 ml Bottle I V | per bottle |
| 24 | Immunoglobulin Human Normal 5% for Intravenous use 5gm (IVIG) 100ml vial | Human Normal Immunoglobulin 5% for Intravenous use 5gm (IVIG) 100ml vial | per vial |
| 25 | Pregabalin 75mg +Methylcobalamin 750mcg Cap | Each hard gelatine capsule contains Pregabalin 75 mg+Methylcobalamin 750mcg+Excipients q.s.OR Equivalent Cap | per tablet |
| 26 | Anti Snake Venom Serum (ASVS) Lyophilysed polyvalent enzyme refined 10ml vial | Anti Snake Venom Serum (ASVS) Lyophilysed polyvalent enzyme refined 10ml vial | per vial |
| 27 | Anti D (Rho D) Immunoglobulin recombinant 300mcg Inj vial/pfs | Anti D (Rho D) Human Immunoglobulin Polyclonal/monoclonol 300mcg Inj | per vial |
| 28 | Albumin Human 20% Inj should contain Na+ content 116-128 mmmol/l in 20% 50ml bottle | Albumin Human 20% Inj should contain Na+ content 116-128 mmmol/l in 20% 50ml bottle | per bottle |

| | | | |
|----|--|---|---------------|
| 29 | Sodium Perborate Monohydrate 810gm (Instrument Sterilant) 5 litre jar | Instrument Sterilant containing : Sodium Perborate Monohydrate 50 % w/w required Compatability report of International Standard Manufacturers for commonly used endoscopes i. e. Karl Storz/ Pentax/Fujinon/ Olympus Required item wise WHO GMP 810gm 5 Litre jar | per can |
| 30 | Formaldehyde solution | Neutral buffered formaldehyde, 10 % w/v for synthesis (A. R. quality),CE notified, owner quality certificate, MSDS | per pack |
| 31 | Chlorhexidine Gluconate 500 ml bottle Surgical scrub | Surgical scrub containing : Chlorhexidine Gluconate 20 % v/v equivalent to Chlorhexidine Gluconate 4 % w/v in Non-Ionic surfactant base (EN Tests required from International Laboratories in Europe / USA) EN1499 Hygienic Hand wash & EN13727 Bactericidal activity Required item wise WHO GMP 500 ml bottle with dispenser | per bottle |
| 32 | Chemical Thermal Textile Disinfection 1 Litre | Polymeric Biguanide Hydrochloride <10%, Alkyl Dimethyl Benzyl Ammonium Chloride & Didecyl Dimethyl Ammonium Chloride <10% (EN Tests Report Required from International Laboratories Europe / USA) EN13697 (Bactericidal and fungicidal activity)EN 16616 (Chemical Thermal Textile Disinfection) 1 Lit. Required item wise WHO GMP 1 litre bottle | per bottle |
| 33 | Rabies Immunoglobulin Human 300 IU/ml Inj 5ml Vial | Rabies Immunoglobulin Human 300 IU/ml Inj 5ml Vial | per vial |
| 34 | Absolute Alcohol | A.R quality ,ISO certified, WHO/GMP ed to and CE notified | per bottle |
| 35 | Ordinary denatured spirit 1000 ml | Ordinary denatured spirit 1000 ml | per bottle |
| 36 | Erythropoietin 20000 I.U. Inj P.F.S. | Erythropoietin 20000 I.U. Inj P.F.S. | per pfs |
| 37 | Dexmedetomidine 100mcg/ml Inj 1ml amp | Dexmedetomidine hydrochloride 100mcg/ml Inj 1ml amp | per ampoule |
| 38 | Tetanus Toxoid Inj 5ml Vial | Tetanus Toxoid Inj 5ml Vial | per vial |
| 39 | Paraffin Wax | (58 C ? 60 C) Non Caking,whogmp/ce certified 1 kg | per container |
| 40 | Insulin Highly Purified Human Neutral Inj (Regular) 40 I.U./ml 10ml vial | Insulin Highly Purified Human Neutral Inj (Regular) 40 I.U./ml 10ml vial | per vial |
| 41 | Dexmedetomidine 100mcg /ml Inj 2 amp | Dexmedetomidine hydrochloride 100mcg/ml Inj 2ml amp | per ampoule |
| 42 | Heparin Low molecular weight 40mg/ 0.4ml Inj PFS | Heparin Low molecular weight 40mg/ 0.4ml Inj PFS | per pfs |
| 43 | Sitagliptin 50 mg Tab | Sitagliptin 50 mg Tab | per tablet |
| 44 | Heparin Low molecular wieght 60mg/0.6ml Inj PFS | Heparin Low molecular wieght 60mg/0.6ml Inj PFS | per pfs |
| 45 | Insulin Aspart 100iu 3ml pfs Inj | Insulin Aspart 100 units/ml 10ml vial Inj | per pfs |
| 46 | Insulin Degludec 100 units/ml 3ml Inj PFP | Insulin Degludec 100 units/ml 3ml Inj PFP | per pfp |
| 47 | Albumin Human 20% Inj 100ml bottle | Albumin Human 20% Inj 100ml bottle | per bottle |

| | | | |
|----|---|---|---------------|
| 48 | Calcium with Vitamin D3 Granules | Sachet Elemental Calcium with Vitamin D3 Granules Each Sachet contains : From an organic source (Oyster shell) Equivalent to Elemental Calcium 500mg + Vitamin D3 IP 250 IU OR EQUIVALENT | per sachet |
| 49 | Cough Suppressant with Diphenhydramine & Guaiphenesin 100 ml Bottle | Cough Suppressant with Diphenhydramine & Guaiphenesin Each 5 ml contains Diphenhydramine HCL IP 8 mg, Guaiphenesin IP 50 mg, Bromhexine HCL IP 4mg, OR Equivalent 100ml Bottle | per bottle |
| 50 | Polyvitamin (Therapeutic) NFI Tab | Polyvitamin (Therapeutic) NFI Tab | per tablet |
| 51 | Xylene (sulphur free) | Sulphur free, Owners quality control certificate, CE notified/WHO GMP conformed | per bottle |
| 52 | Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Ioversol 100ml vial | Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Ioversol | per vial |
| 53 | Formalin solution (37 to 40 %) | 37 to 40 % w/v for synthesis (A. R. quality),CE notified, owner quality certificate | per can |
| 54 | Surfactant for Intratrecheal instillation (natural bovine lung surfactant) Minimum labelled Shelf Life (In Months 18) 8ml | Surfactant for Intratrecheal instillation (natural bovine lung surfactant) Minimum labelled Shelf Life (In Months 18) 8ml | per vial |
| 55 | Streptokinase 15 Lac I.U. Inj | Streptokinase 15 Lac I.U. Inj single dose | per vial |
| 56 | White soft paraffin 500gms | white soft paraffin 500gms | per container |
| 57 | Octreotide 100mcg/ml Inj 1ml amp | Octreotide 100mcg/ml Inj 1ml amp | per ampoule |
| 58 | Trifluoperazine 5 mg Tab | Trifluoperazine 5 mg Tab | per tablet |
| 59 | Iso-Propyl Alcohol | AR grade Mol weight 60.10, minimum assay 99.5% | per bottle |
| 60 | Sitagliptin 100 mg Tab | Sitagliptin 100 mg Tab | per tablet |
| 61 | Levosulbutamol 1.25mg + Ipratropium 500mcg Respules 3ml | Levosulbutamol 1.25mg + Ipratropium 500mcg Respules 3ml | per respules |
| 62 | Thiamine (Vitamin B1) 200mg/2ml Inj | Thiamine (Vitamin B1) 200mg/2ml Inj | per vial |
| 63 | Erythropoietin 4000IU/1.0ml Inj PFS | Erythropoietin 4000IU Vial/1.0ml Inj PFS | per pfs |
| 64 | Flucinolone Acetonide Cream 0.1% w/w | Flucinolone Acetonide Cream 0.1% w/w | per tube |
| 65 | Heparin Sodium 5000 I.U./ml Inj 5ml Vial | Heparin Sodium 5000 I.U./ml Inj 5ml Vial | per vial |
| 66 | Rabies Antiserum 1500 IU/5ml Inj IM & SC | Rabies Antiserum 1500IU/5ml Inj IM & SC | per vial |
| 67 | Colistomethate 1 MIU Inj | Colistimethate sodium 1 million iu Inj | per vial |
| 68 | Erythropoietin 2000 I.U. Inj P.F.S. | Erythropoietin 2000 I.U. Inj P.F.S. | per pfs |
| 69 | Cough Expectorant with Dextromethorphan Hydrobromide 100ml Bottle | Cough Expectorant with Dextromethorphan Hydrobromide Each 10ml Contains Dextromethorphan Hydrobromide I.P. 10mg, Chlorpheniramine Maleate I.P.4mg, Guaiphenesin I.P. 100mg, Alcohol (95%) 0.2ml, OR Equivalent 100ml Bottle | per bottle |

| | | | |
|----|---|---|-----------------|
| 70 | Cough Syrup (HBPCL Reserved) 100ml Bottle | Each 5 ml Contains Diphenhydramine 15 mg, Ammonium chloride 150 mg, Sodium citrate 60 mg, Menthol 1 mg, and Flavoured Base Colour : Ponceau 4 R Or Equivalent 100ml Bottle | per bottle |
| 71 | Inj. Suxamethonium Hydrochloride 50mg/ml | Inj. Suxamethonium Chloride 50 mg/ml - 2 ml Ampoule | 2 ml Ampoule |
| 72 | Streptokinase Inj. 7.5Lac | Inj.Streptokinase 7.5 lacs/Vial | Vial |
| 73 | Tuberculin, Purified Protein derivative Inj 1TU 5TU | PPD test for purified protein derivative TUBERCULIN PPD RT/23 2TU OR TUBERCULIN PPD RT/23 5TU Vials of 1,5 mL containing 5 TU per 0,1 mL packed in boxes of 10 Vials | 1.5 ml |
| 74 | Penamavir Inj. 200mg I.V. | Penamavir Inj. 200mg I.V. | 100ml |
| 75 | Urokinase Inj. 5 Lac IU | Inj. Urokinase 5,00,000 iu | Vial |
| 76 | Urokinase Inj. 10 Lac IU | Inj. Urokinase 10,00,000 iu | Vial |
| 77 | Streptokinase Inj. 7.5Lac | Inj.Streptokinase 7.5 lacs/Vial | Vial |
| 78 | Inj. Tenecteplase 20 mg | Inj. Tenecteplase 20mg Vial | Pack of 2 Vials |
| 79 | Inj. Tenecteplase 40mg | Inj. Tenecteplase 40mg Vial | Vial |
| 80 | Inj. Retiplase 18mg (Pack of 2 Vials) | Inj. Retiplase 18mg Contains Retiplase Recombinant Tissue Plasminogen Activator 18mg | Vial |
| 81 | Heparin Sodium Inj. 1000 IU/ml | Inj. Heparin sodium 1000 I U/ml - 5 ml Vial | 1ml Amp. |
| 82 | Inj. Vasopressin 20 IU, 1ml | Inj. Vasopressin 20 IU 1ml Each 1 ml contains 20 IU Vasopressin, Chlorbutol IP 0.5% w/v (as preservative) Water for Injections IP q.s. | Vial |
| 83 | Prostaglandin E1 Inj | Prostaglandin E1 Inj - 10 µg/ml Vial or 20 µg/ml Vial or 40 µg/ml Vial | Vial |
| 84 | Plasma Volume Expander 500ml FFS Pack | Each 100 ml IV Fluid Contains : Polygeline Polypeptides of degraded gelatin, cross linked via urea bridges 3.5g (Equivalent to 0.63g of notrogen) Sodium Chloride IP 0.85g Potassium Chloride IP 0.038g Calcium Chloride IP 0.070g Water for Injection IP q.s. Electrolytes in m. mol/ Litre Na+ 145, K+ 5.1, Ca++ 6.25, Cl- 145 Mean Molecular Weight 30000 pH of infusion solution 7.3+0.3 | Vial |

| | | | |
|----|---|---|------|
| 85 | Anti Hemophilic Factor VIII | <p>1. Freeze dried, lyophilized, Intermediate to high purity, NAT tested, with varying amounts of Von Willebrand factor , depending upon method of preparation as per BP, USP, IP or EP</p> <p>2. Factor concentrate should be prepared from well verified source plasma, which is individually tested for Hepatitis-B, Hepatitis-C & HIV 1 & 2 by Nucleic acid Amplification Test (NAT. Test) & should have been tested Negative and have undergone at least 2 dedicated viral removal and 2 viral inactivation steps as per WFH guidelines.</p> <p>3. Expiry date should not be less than one Year.</p> <p>4. Factors must dissolve within 10 mins with transparent appearance as per BP, USP, IP or EP</p> <p>5. International Standard of Purity as defined by WFH Guideline Factor</p> <p>6. Factor must have at least BP, USP, IP or EP</p> <p>7. Safety and Efficacy standards as per WFH guidelines for Clotting Factors Concentrates (CFC) Assessment</p> <p>8. Pathogen Inactivation / Viral removal method used for enveloped and non-enveloped pathogens for CFC</p> <p>9. No human and animal derived proteins should have been used during manufacture or formulation of recombinant products.</p> <p>10. Package shall contain the sterile water for injection</p> | Vial |
| 86 | Anti Hemophilic Factor Viii Bypassing Agent (FEIBA) | <p>1. Factor concentrate should be prepared from well verified source plasma, which is individually tested for Hepatitis-B, Hepatitis-C & HIV 1 & 2 by Nucleic acid Amplification Test (NAT. Test) & should have been tested Negative and have undergone at least 2 dedicated viral removal and 2 viral inactivation steps as per WFH guidelines.</p> <p>2. Package shall contain the sterile water for injection</p> <p>3. Anti-Hemophilic factor should be sterile, non-pyrogenic and dried form</p> <p>4. Expiry date should not be less than one Year.</p> <p>5 Factors must dissolve within 10 mins with transparent appearance as per WFH Guidelines.</p> <p>6. International Standard of Purity as defined by WFH Guideline Factor Concentrates .</p> <p>7. Factor must have at least BP, USP, IP or EP</p> <p>8. Safety and Efficacy standards as per WFH guidelines for Clotting Factors Concentrates (CFC) Assessment</p> <p>9. Pathogen Inactivation / Viral removal method used for enveloped and non-enveloped pathogens for CFC</p> <p>10. No human and animal derived proteins should have been used during manufacture or formulation of recombinant products</p> | Vial |
| 87 | Anti Hemophilic Factor vii | <p>1. Activated, Human recombinant coagulation factor VII Vial</p> <p>2. Package shall contain the sterile water for injection</p> <p>3. Anti-Hemophilic factor should be sterile, non pyrogenic and dried form</p> <p>4. Expiry date should not be less than one Year</p> | Vial |
| 88 | Anti Hemophilic Factor VIII | <p>1. Ultra pure Recombinant Factor VIII- Plasma free, Human Albumin free inj</p> <p>2. Reconstitute in 2 or 4 mldilution</p> <p>3. Expiry date should not be less than one Year</p> | Vial |

| | | | |
|----|--|---|--------|
| 89 | Anti Hemophilic Factor VIII | 1. Ultra pure Recombinant Factor VIII- Plasma free, Human Albumin free inj 2. Reconstitute in 2 or 4 mldilution 3. Expiry date should not be less than one Year | Vial |
| 90 | Anti Hemophilic Factor VIII | 1. Ultra pure Recombinant Factor VIII- Plasma free, Human Albumin free inj 2. Reconstitute in 2 or 4 mldilution 3. Expiry date should not be less than one Year | Vial |
| 91 | Anti Hemophilic Factor IX | 1. Ultra pure Recombinant Factor IX- Plasma free, Human Albumin free inj 2. Expiry date should not be less than one Year | Vial |
| 92 | Anti Hemophilic Factor IX | 1. Ultra pure Recombinant Factor IX- Plasma free, Human Albumin free inj 2. Expiry date should not be less than one Year | Vial |
| 93 | Anti Hemophilic Factor IX | 1. Ultra pure Recombinant Factor IX- Plasma free, Human Albumin free inj 2. Expiry date should not be less than one Year | Vial |
| 94 | Anti Hemophilic FACTOR IX | 1. Freeze dried, lyophilized, high purity, NAT tested, factor IX 2. Factor concentrate should be prepared from well verified source plasma, which is individually tested for Hepatitis-B, Hepatitis-C & HIV 1 & 2 by Nucleic acid Amplification Test (NAT. Test) & should have been tested Negative and have undergone at least 2 dedicated viral removal and 2 viral inactivation steps as per WFH guidelines. 3. Expiry date should not be less than one Year. 4. Factors must dissolve within 10 mins with transparent appearance as per BP, USP, IP or EP 5. International Standard of Purity as defined by WFH Guideline Factor 6. Factor must have at least BP, USP, IP or EP 7. Safety and Efficacy standards as per WFH guidelines for Clotting Factors Concentrates (CFC) Assessment 8. Pathogen Inactivation / Viral removal method used for enveloped and non-enveloped pathogens for CFC 9. No human and animal derived proteins should have been used during manufacture or formulation of recombinant products. | 100 ml |
| 95 | Hepatitis B Immunoglobulin 100 i. u. | Hepatitis B Immunoglobulin 100 i. u. IM Single Dose | 50 ml |
| 96 | Hepatitis B Immunoglobulin 200 i. u. | Hepatitis B Immunoglobulin 200 i. u. IM Single Dose | 250 ml |
| 97 | Factor VII | Activated, Human recombinant coagulation factor VII (r-DNA origin) 1mg Vial containing 50,000 units of factor VII. | Vial |
| 98 | Inj. Human Albumin 20% (Low Salt), 50 ml | Inj. Human Albumin 20% (Low Salt) 50 ml infusion bottle | 10 ml |
| 99 | Inj. Human Albumin 5% (Isotonic), 250 ml | Inj. Human Albumin 5% (Isotonic) 250 ml infusion bottle | 10 ml |

| | | | |
|-----|--|---|---------------|
| 100 | Cryoprecipitate | Cryoprecipitate is a component prepared by thawing a unit of fresh frozen plasma at 4°C and then recovering the cold-precipitated factor VIII protein by centrifugation. The usual unit contains an average of 80 units of factor VIII and at least 150 mg of fibrinogen in about 15 mL of plasma. Jumbo cryoprecipitate is produced as a byproduct from cryo-poor plasma collected by cytopheresis from a single donor. One unit of jumbo cryoprecipitate equals at least 3 standard units of cryoprecipitate in its composition of factor VIII and fibrinogen. | 2 ml |
| 101 | Filgrastim Inj. 300mcg | Inj Filgrastim 300 mcg per Vial-PFS | 5 ml |
| 102 | Antisnake Venom Serum sterile powder with sterile water, lyophilized sterile solution 10ml | Inj. ASVS (Antivenum Lypholysed polyvalent Antisnake venom Serum Inj. (Polyvalent Inj) enzyme refined 10 ml | 10 ml |
| 103 | Snake Venom Antiserum Lyophilized Polyvalent Powder for Injection 10ml | Snake Venom Antiserum Polyvalent Snake Venom Antiserum Lyophilized Powder for Injection 10ml Vial With Water for Injection q.s. | 1 ml Vial |
| 104 | Rabies immunoglobulin - Anti Rabies Serum | Human derived anti-rabies immunoglobulin 150 I U per ml - i.e. 300 IU per 2 ml PFS | 1 ml Vial |
| 105 | Diphtheria Antitoxin Inj | Human Normal immunoglobulin inj for diphtheria OR Diphtheria antitoxin 10,000 i.u.- 5 ml | 1 ml / 0.5 ml |
| 106 | Antiscorpion Venum Serum Inj. 10ml | Antiscorpion Venum Serum Inj. 10ml | 2.5 ml |
| 107 | Antitetanus Human immunoglobulin Inj | Each Vial contains Human Tetanus Immunoglobulin Equivalent to Tetanus antitoxin 250 I. U. STabilizer: Glycine . 0.3 M Preservative: Thiomersal 0.01% w/v - 1 ml | 0.5 ml Amp |
| 108 | Antitetanus Human immunoglobulin Inj | Each Vial contains Human Tetanus Immunoglobulin Equivalent to Tetanus antitoxin 500 I. U. STabilizer: Glycine 0.3 M Preservative: Thiomersal 0.01% w/v - 1 ml | 10 ml Vial |
| 109 | Anti Rabies Vaccine ID / IM (for Both ID/IM Use) | Anti Rabies vaccine Tissue culture 2.5 I U per Vial or amp or Purified vero cell Rabies vaccine 2.5 IU per Vial or amp or purified chick embryo vaccine 2.5 I U per Vial or amp & Sterile water for injection as diluents, <u>Label should indicate for ID / IM use</u> Ampoule/Vial of 1 ml or 0.5ml | 10 ml Vial |
| 110 | Rabies Human Monoclonal Antibody (r-DNA origin) 100 IU/2.5 ml | Recombinant Rabies Human Monoclonal Antibody (r-DNA origin) 100 IU/2.5 ml | 10 ml Vial |

| | | | |
|-----|---|--|-----------------------------|
| 111 | Fresh frozen plasma | A unit of fresh frozen plasma contains all coagulation factors including the labile plasma coagulation factors VIII and V. An adult dose contains approximately 200 IU of factor VIII. 1.Fresh frozen plasma (Double split) Volume 250–334 mL,Factor VIIIc > 0.7 IU/mL 2.Fresh frozen plasma (Triple split) Volume 250–310 mL,Factor VIIIc > 0.7 IU/mL 3. Fresh frozen plasma (Paediatric) Volume 63–81 mL,Factor VIIIc > 0.7 IU/m | |
| 112 | Hydroxyethyl Starch (Hetastarch) Inj 6% 500ml | I.V. Hydroxyethyl starch 6% IPHydroxyethyl starch 130/04, 6% saline solution Plasma Volume Expander IV 1) 6% Hydroxy Ethyl Starch 2) Low mean molecular wt. From 1,00,000- 1,50,000 daltons 3) High dose flexibility up to 50mls/ kg. b.w./day 4) Minimal interference in coagulation mechanism, grouping cross matching. 5) Low risk of anaphylaxis 6) Bottle of 500ml. | 500 ml bottle |
| 113 | Human Insulin plain 40iu/ml | Highly purified human neutral insulin 40iu/ml - 10 ml | 10 ml |
| 114 | Human Insulin NPH/Isophane 40iu/ml | Highly purified bovine porcine isophane insulin susp 40 i.u./ml NPH insulin (or neutral protamine Hagedorn) (also known as Humulin N, Novolin N, Novolin NPH, NPH Iletin II, and isophane insulin), | 10 ml |
| 115 | Human Insulin PZI 40 iu/ml | Human Insulin Protamine Zinc Insulin (PZI) 40 IU /ml | 3 ml PFS |
| 116 | Human Insulin analogues- lispro | Mono component human insulin analog lispro100 IU/ML 3 ml cartridge.pack of 5 | 3 ml PFS |
| 117 | Premix Insulin 30:70 injection | Recombinant human insulin biphasic 30%, Regular 70% 100 iu/ml | 1.5 ml Cartridge (Box of 3) |
| 118 | Insulin Lispro Mix 25/75 or 30/70 pen with needle Pack size - 1 pen with needle | 25% Insulin Lispro (rDNA origin) and 75% Insulin Lispro protamine suspension 100 IU/ml - ml Pen with needle or 30% Insulin Lispro (rDNA origin) and 70% Insulin Lispro protamine suspension 100 IU/ml - ml Pen with needle | pfs/ single dose Vial |
| 119 | Premix Biphasic Insulin Analogue 30:70 injection | Premix Biphasic Insulin Analogue 30:70 injection Recombinant Insulin 30%, Regular 70%, 100 IU/ml | Vial |
| 120 | Basal Insulin Analogue : Insulin 100 IU/ml | Basal Insulin Analogue : Insulin 100 IU/ml, 3 ml PFS | Vial |
| 121 | Glargine 300 IU/ml, 1.5 ml Cartridge | Glargine 300 IU/ml, 1.5 ml Cartridge | 5 ml Vial |
| 122 | Mesna Inj. 200mg | Inj. Mesna 200 mg Vial | Vial |
| 123 | Inj. Filgrastim 300mcg | Inj. Filgrastim 300mcg SC / IV Infusion | Vial |

| | | | |
|-----|---|--|---------------------------------|
| 124 | Actinomycin D Inj. 0.5mg | Inj. Dactinomycin 0.5mg | 100ml Bottle/250ml Bottle |
| 125 | Inj. Interferon alfa-2a 3m iu | Inj. Interferon alfa-2a 3m iu | 90 ml |
| 126 | 5 - Flurouracil Inj. | Inj. 5 Fluorouracil 250 mg/5 mL Vial | 90 ml |
| 127 | Iron Silver Stream (Low concentrated) Solution 100 ml (Silver Stream) 100ml | Iron Silver Stream (Low concentrated silver ion (0.01%) Menthol, Glycerol, tween-20 and Tris Buffer) in solution form 100 ml | 90 ml |
| 128 | Iron Silver Stream (Low concentrated) Solution 250 ml (Silver Stream) 250ml | Iron Silver Stream (Low concentrated silver ion (0.01%) Menthol, Glycerol, tween-20 and Tris Buffer) in solution form 250 ml (Silver Stream) | 90 ml |
| 129 | Iopromide Contrast 50ml | Iopromide 300 mgI/mL OR Iopromide 370 mgI/mL Glass Vials of 90ml | 90 ml |
| 130 | Inj Ioversol 350-74% Contrast Media for IVP,HSG or CT | Inj Ioversol 350-74% Contrast Media for IVP,HSG or CT | 90 ml |
| 131 | Inj Ioversol 320 - 68% Contrast Media for IVP,HSG or CT | Inj Ioversol 320 - 68% Contrast Media for IVP,HSG or CT | 10 ml |
| 132 | Inj Ioversol 300 - 64% | Inj Ioversol 300 - 64% | 1440 ml |
| 133 | Inj Ioversol 240 - 51% Contrast Media for IVP,HSG or CT | Inj Ioversol 240 - 51% Contrast Media for IVP,HSG or CT | 90ml |
| 134 | Inj Ioversol 160 - 34% Contrast Media for IVP,HSG or CT | Inj Ioversol 160 - 34% Contrast Media for IVP,HSG or CT | 90ml |
| 135 | Gadodiamide inj. 0.5mmol/ 10ml | Inj Gadobenate Dimglumin Inj 0.5mmol / 10 ml | 10ml |
| 136 | Total Parenteral Nutrition 1.440 ltr | Total Parenteral Nutrition 1.440 ltr contains All in One multi chamber bag for Parenteral Nutrition in 1440ml, providing 1000kcal with intravenous Amino Acids 34gm containing lipid emulsion 51gm and glucose 97gm. Having Osmolarity of 750 mosm/L with Glucose to Lipid ratio of 44:56 with Sterile Self - Sealing parts which are along stable and have tamper evident arrow flaps | 1440ml |
| 137 | Intra Ocular Lenses | Material PMMA Optic Design-Biconvex Optic Size-5.25 mm to 6.00mm Length-12.00mm to 13.00mm Angulation – 10 Degrees Vault height 0.4 Haptic- modified 'C' loop A-Constant-118.0 to 118.4 Holes-2 Dialing Holes Power Ranges-8.0 to 30.00 D (0.50D increments) Optics-PMMA with UV absorber Lathe cut & Tumble Polished Sterllization: Eto Sterilised | Each |

Laboratory should send the drug testing results as stipulated in the table below:

| Sr. No. | Description | Sample collection Period | Testing Period of Sample | Delivery of analysis report of sample tested |
|----------------|---|---------------------------------|---------------------------------|---|
| 1 | Tablets, Capsules, Pessaries, Ointments, Powder and Liquid , Oral Preparations etc. | Within 24 Hrs. | 10 days | On same day or next day of testing period |
| 2 | Injection, I V Fluid | Within 24 Hrs. | 21 days | On same day or next day of testing period |
| 3 | Laboratory Chemicals & Kits | Within 24 Hrs. | 10 days | On same day or next day of testing period |

Submission Requirements:

Laboratories shall submit:

- Detailed Financial Quotation (Per test Per Item).
- Copies of all mandatory certificates (Testing License issued by FDA, NABL, GLP).
- Company profile and address of laboratory/testing location.
- Contact details of the authorized representative.
- Last date & time for Submission of quotation: Dt: 24.11.2025 15:00 Hrs.
- Physical copy of quotation shall be submitted in the name of Chief Executive Officer, Maharashtra Medical Goods Procurement Authority, 1st Floor, Aarogya Bhawan, Commissionerate of Health Services, Mumbai, D'Mello Road, St. Georges Hospital Compound, Mumbai 400001, on or before the last date and time fixed for the submission of quotation.

Terms & Conditions:

1. Rates should be quoted inclusive of all taxes.
2. Quotation must be valid for minimum 90 days from the date of submission.
3. All tests must be conducted strictly as per relevant pharmacopeia guidelines.
4. Any deviation in test method must be informed and approved beforehand.
5. For any delay more than the period stipulated in the table above, as the case may be, 0.5% of the testing charges per day (Maximum up to 10%) and the part thereof would be deducted as penalty.
6. Payment shall be made after receipt of final authorised test reports.
7. The Purchaser reserves the right to reject any quotation without assigning reasons.
8. The rates shall remain valid for a period of one (1) year from the date of award.
9. Last date & time for Submission of quotation:

Last Date & Mode of Submission:

Quotations must be submitted on or before:

Date: Dt: 25.11.2025

Time: 15:00 Hrs.

Mode: Physical copies to be submitted

|

Annexure-I

DETAILS OF THE BIDDER

| | | |
|---|---|---|
| a | Name of Firm | |
| | Office Address | |
| | Telephone and Fax Number | |
| b | Works Address | |
| | Telephone and Fax Number | |
| c | Name of the Authorized Signatory of the Tender, Phone/ Mobile Phone No. Email ID | |
| d | Name of the Contact person Phone/Mobile Phone No. Email ID | |
| e | Status of the Bidder (such as Govt Organization/Undertaking, Public/Private Ltd Co, Partnership Firm, HUF, SSLI,) | |
| f | Registration Firm/Incorporation of the bidding Company/Establishment Registration Details No | Registration of Firm/Incorporating of Company/Establishment Registration and Date..... |
| g | Details of Manufacturing unit if any held by the laboratory(bidder) or associated/group entity involved in manufacturing of any of the Drugs/Medical Devices/ Chemicals/Miscellaneous items, being manufactured by themselves/associated/group entity or an entity having common board of director/s or partner/s. | Name of the Manufacturer/s: Address of the Manufacturer/s: Details of products manufactured: |
| h | GST Registration | No.....and Date..... |
| i | Details of NABL Certificate | No..... Date Valid up to |
| j | Details of GLP Certificate | No..... Date Valid up to |
| k | Details of ISO Certificate | No..... Date Valid up to |
| l | a) Details of Bank account with IFSC Code | |

Annexure-2

COMMERCIAL BID FORMAT

| Sr. No. | Drug Name | Technical Specification | Packing | Rate of Sample Testing | Qty in nos | Basic Cost per Test (exclusive of GST) | GST applicable for Govt. Supply | Other incidental charges (Please specify) (In Rs.) | Total landed cost per TEST (6+7+8) | Total Cost Rs.Per Test (5*9) |
|---------|-----------|-------------------------|---------|------------------------|------------|--|---------------------------------|---|------------------------------------|------------------------------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |